Toggle navigation
Home
Search
Services
Blog
Contact
About
Production and Testing of Anthrax Recombinant Protective Antigen /Rpa/-266030053
Vaxgen Inc.
Search grants from Vaxgen Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Roles for Intracellular pH Dynamics in Cancer Cell Behaviors
Efficacy of flupirtine for treatment of neonatal hypoxic-ischemic encephalopathy
Hurricane Katrina Relief Efforts
106-Kda CA2+ Release Channels in Sr
New, GK-12: Growing the Green Collar Workforce for the 21st Century
Recently added grants:
Proteomics and phosphoproteomics analysis in HIV-1 infection
Thrombocyte Regulation of Anti-Parasite Immunity
Using gravity to perceive, move and orient
Structure/Function of Protein Tyrosine Phosphatases
Survival and Recurrence of Dormant Cancer Cells
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI030053-007
Application #
7191311
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2005
Total Cost
Indirect Cost
Institution
Name
Vaxgen Inc.
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2006
N01 AI
Production and Testing of Anthrax Recombinant Protective Antigen /Rpa/-266030053
/ Vaxgen Inc.
NIH 2005
N01 AI
Production and Testing of Anthrax Recombinant Protective Antigen /Rpa/-266030053
/ Vaxgen Inc.
NIH 2004
N01 AI
Production and Testing of rPA Vaccine-26630053
/ Vaxgen Inc.
NIH 2003
N01 AI
Production and Testing of Anthrax Recombinant Protective Antigen Vacci-
/ Vaxgen Inc.
Publications
Omland, Kristian S; Brys, April; Lansky, David et al.
(2008)
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.
Clin Vaccine Immunol 15:946-53
Comments
Be the first to comment on this grant